Hypoxia-Inducible Factor–Prolyl Hydroxyl Domain Inhibitors: From Theoretical Superiority to Clinical Noninferiority Compared with Current ESAs?

F Locatelli, L Del Vecchio - Journal of the American Society of …, 2022 - journals.lww.com
Anemia is a common complication of chronic kidney disease; it is mainly treated with
erythropoiesis-stimulating agents (ESAs) and iron. Experimental studies extensively …
被引用次数：20 相关文章

Hypoxia-Inducible Factor-Prolyl Hydroxyl Domain Inhibitors: From Theoretical Superiority to Clinical Noninferiority Compared with Current ESAs?

F Locatelli, L Del Vecchio - Journal of the American …, 2022 - pubmed.ncbi.nlm.nih.gov
Anemia is a common complication of chronic kidney disease; it is mainly treated with
erythropoiesis-stimulating agents (ESAs) and iron. Experimental studies extensively …

Hypoxia-Inducible Factor–Prolyl Hydroxyl Domain Inhibitors: From Theoretical Superiority to Clinical Noninferiority Compared with Current ESAs?

F Locatelli, L Del Vecchio - … Journal of the American Society of …, 2022 - ingentaconnect.com
Anemia is a common complication of chronic kidney disease; it is mainly treated with
erythropoiesis-stimulating agents (ESAs) and iron. Experimental studies extensively …
[HTML] nih.gov

[HTML][HTML] Hypoxia-Inducible Factor–Prolyl Hydroxyl Domain Inhibitors: From Theoretical Superiority to Clinical Noninferiority Compared with Current ESAs?

F Locatelli, L Del Vecchio - Journal of the American Society of …, 2022 - ncbi.nlm.nih.gov
Anemia is a common complication of chronic kidney disease; it is mainly treated with
erythropoiesis-stimulating agents (ESAs) and iron. Experimental studies extensively …

Hypoxia-Inducible Factor-Prolyl Hydroxyl Domain Inhibitors: From Theoretical Superiority to Clinical Noninferiority Compared with Current ESAs?

F Locatelli, L Del Vecchio - Journal of the American Society of …, 2022 - europepmc.org
Anemia is a common complication of chronic kidney disease; it is mainly treated with
erythropoiesis-stimulating agents (ESAs) and iron. Experimental studies extensively …

Hypoxia-Inducible Factor–Prolyl Hydroxyl Domain Inhibitors: From Theoretical Superiority to Clinical Noninferiority Compared with Current ESAs?

F Locatelli, L Del Vecchio - Journal of the American Society of …, 2022 - cir.nii.ac.jp
抄録< jats: p> Anemia is a common complication of chronic kidney disease; it is mainly
treated with erythropoiesis-stimulating agents (ESAs) and iron. Experimental studies …

Hypoxia-Inducible Factor-Prolyl Hydroxyl Domain Inhibitors: From Theoretical Superiority to Clinical Non-inferiority Compared to Current ESAs?

F Locatelli, L Del Vecchio - Journal of the American Society of …, 2022 - europepmc.org
Anemia is a common complication of chronic kidney disease; it is mainly treated with
erythropoiesis-stimulating agents (ESA) and iron. Experimental studies extensively …